Genistein nanoparticle - Humanetics Corporation
Alternative Names: BIO-300Latest Information Update: 13 Aug 2024
At a glance
- Originator Armed Forces Radiobiology Research Institute; National Institutes of Health (USA); United States Department of Defense
- Developer Armed Forces Radiobiology Research Institute; Henry Ford Health System; Humanetics Corporation; Medical College of Wisconsin; Milwaukee VA Medical Center; National Institutes of Health (USA); University of Maryland, Baltimore
- Class Antifibrotics; Antineoplastics; Chemosensitisers; Isoflavones; Osteoporosis therapies; Phytotherapies; Radioprotectives; Small molecules
- Mechanism of Action Antioxidants; Apoptosis inhibitors; Apoptosis stimulants; Cell cycle modulators; DNA repair enzyme modulators; Haematopoietic cell growth factor stimulants; Inflammation mediator modulators; Protein tyrosine kinase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pulmonary fibrosis
- Phase I/II Radiation injuries
- Phase I Acute radiation syndrome
Most Recent Events
- 09 Aug 2024 Minneapolis-based Humanetics Corporation (Humanetics) entered into cooperative research agreement with Armed Forces Radiobiology Research Institute (AFRRI) to continue advanced development of BIO 300
- 19 Sep 2023 Efficacy, pharmacokinetics and adverse events data from a phase-I/II trial in Radiation injuries released by Humanetics Corporation
- 24 May 2023 Pharmacodynamics data from a non-clinical trial in Radiation injuries released by Humanetics Corporation